【摘要】： 目的:對(duì)小兒腎母細(xì)胞瘤新型疫苗進(jìn)行初步探索、研究,為該腫瘤的治療以及替代手術(shù)后的放、化療提供新的切入點(diǎn)。 方法:首先對(duì)必需的實(shí)驗(yàn)材料進(jìn)行制備和驗(yàn)證,包括抗體的制備和腫瘤細(xì)胞模型的建立。針對(duì)小兒腎母細(xì)胞瘤WT1基因,選取兩段抗原表位肽HLA-A*0201、HLA-A*2402采用構(gòu)建DNA疫苗的方式,運(yùn)用Balb/c小鼠免疫檢測(cè)的方法篩選最佳的抗原表位肽,為小兒腎母細(xì)胞瘤新型疫苗的研究奠定基礎(chǔ)。用篩選得到的表位肽HLA-A*2402構(gòu)建DNA疫苗,為最終新型疫苗的研制做對(duì)照。采用基因重組技術(shù)分別克隆編碼小兒腎母細(xì)胞瘤WT1表位肽HLA-A*2402融合到乙型肝炎核蛋白基因片段(HBc)上,運(yùn)用桿狀病毒表達(dá)系統(tǒng)對(duì)融合蛋白進(jìn)行表達(dá),通過電鏡觀察得到的融合蛋白呈病毒樣顆粒(VLP)。繼而采用WB技術(shù)對(duì)表達(dá)的蛋白進(jìn)行鑒定。鑒定好的VLP蛋白和DNA疫苗采用細(xì)胞模型進(jìn)行研究,然后分別免疫Balb/c小鼠,采用ELISA、FCM、MTS等免疫學(xué)實(shí)驗(yàn)技術(shù)分別檢測(cè),初步判斷基于WT1表位肽HLA-A*2402構(gòu)建的以VLP為呈現(xiàn)載體的重組蛋白,作為該腫瘤治療以及替代手術(shù)后的放、化療的可行性。 結(jié)果: (1)制備了合格的實(shí)驗(yàn)材料:對(duì)小兒腎母細(xì)胞瘤細(xì)胞進(jìn)行了成功的原代培養(yǎng),建立了細(xì)胞系用于實(shí)驗(yàn)研究;克隆了WT1基因部分片段的原核表達(dá)質(zhì)粒,表達(dá)并純化了蛋白,免疫家兔,采集血清制備了針對(duì)WT1的多克隆抗體。 (2) MTS及FCM初步證明,短肽HLA-A*2402在刺激淋巴細(xì)胞增殖方面優(yōu)于HLA-A*0201,而前者無顯著性差異(p0.05)。因此,HLA-A*2402為我們選擇深入研究的對(duì)象。 (3)構(gòu)建了含有HLA-A*2402的DNA疫苗,雙酶切和測(cè)序結(jié)果證明構(gòu)建成功。 (4)構(gòu)建了HBc與HLA-A*2402偶聯(lián)(couple)的以VLP為呈現(xiàn)載體的新型疫苗,雙酶切和測(cè)序結(jié)果證明構(gòu)建成功。運(yùn)用桿狀病毒表達(dá)系統(tǒng)對(duì)偶聯(lián)的蛋白進(jìn)行表達(dá),WB和電鏡檢測(cè)證明目的蛋白的表達(dá)。 (5)運(yùn)用以VLP為呈現(xiàn)載體的新型疫苗進(jìn)行Balb/c小鼠的免疫,并以構(gòu)建的DNA疫苗作為對(duì)照,結(jié)果表明以VLP為呈現(xiàn)載體的新型疫苗免疫小鼠產(chǎn)生了有效的特異性體液免疫和細(xì)胞免疫�？贵w亞型分類表明特異性IgG1/IgG2a小于1,說明產(chǎn)生了Th1型為主的免疫應(yīng)答。T淋巴細(xì)胞增殖試驗(yàn)證實(shí)免疫小鼠脾臟T淋巴細(xì)胞對(duì)ConA誘導(dǎo)的增殖反應(yīng)增強(qiáng);ELISPOT分析表明疫苗免疫組的特異性活化的可分泌IFN-γ的CD8+T細(xì)胞數(shù)顯著多于對(duì)照組;FCM檢測(cè)表明,疫苗免疫組的CD4+/CD8+比值顯著低于對(duì)照組。這些結(jié)果提示以VLP為呈現(xiàn)載體的新型疫苗誘導(dǎo)了特異性CD8+T淋巴細(xì)胞應(yīng)答。其激發(fā)的細(xì)胞免疫和體液免疫均明顯優(yōu)于DNA疫苗對(duì)照組。 (6)研究證實(shí)HLA-A*2402在小兒腎母細(xì)胞瘤的免疫治療過程中扮演著重要的角色,而以VLP為呈現(xiàn)載體的新型疫苗為腫瘤的免疫治療提供了新的思路。 結(jié)論:所制備的小兒腎母細(xì)胞瘤以VLP為呈現(xiàn)載體的新型疫苗在小鼠體內(nèi)可同時(shí)激發(fā)體液免疫和細(xì)胞免疫,優(yōu)于相應(yīng)的DNA疫苗,為腫瘤的免疫治療提供新的方法和思路。更為重要的是將病毒有關(guān)成分引入到腫瘤的免疫治療中,其良好的實(shí)驗(yàn)結(jié)果有待于腫瘤動(dòng)物模型的進(jìn)一步驗(yàn)證。
[Abstract]:Objective: To explore a new vaccine for Wilms tumor in children, and to provide a new breakthrough point for the treatment of this tumor and for postoperative radiotherapy and chemotherapy.
Methods: first, the necessary experimental materials were prepared and verified, including the preparation of the antibody and the establishment of the tumor cell model. According to the WT1 gene of the nephroblastoma in children, the two segment epitope peptide HLA-A*0201 was selected, and HLA-A*2402 was used to construct the DNA vaccine, and the best epitope peptide was screened by the method of immune detection in Balb/c mice. For the study of a new type of vaccine for nephroblastoma, the DNA vaccine was constructed with the selected epitope peptide HLA-A*2402, which was used as the control for the development of the final new vaccine. The gene recombination technique was used to clone the WT1 epitope peptide HLA-A*2402 of the children's nephroblastoma to the hepatitis B nucleoprotein gene fragment (HBc) and use the pole shape. The fusion protein was expressed by the virus expression system. The fusion protein obtained by electron microscopy was virus like particles (VLP). Then WB technology was used to identify the expressed protein. The identified VLP protein and DNA vaccine were studied by cell model, and then immune Balb/ c mice were immunized with ELISA, FCM, MTS and other immunoassay techniques. The preliminary determination of the recombinant protein based on the WT1 epitope peptide HLA-A*2402, based on the VLP as the carrier, was used as the tumor therapy and the possibility of chemotherapy after the replacement of the tumor.
Result:
(1) the qualified experimental materials were prepared: the primary culture of the children's nephroblastoma cells was successfully cultured, the cell line was established for experimental study, the prokaryotic expression plasmid of the partial fragment of WT1 gene was cloned, the protein was expressed and purified, the rabbit was immunized, and the polyclonal antibody against WT1 was prepared by the collection of serum.
(2) MTS and FCM preliminarily proved that the short peptide HLA-A*2402 is superior to HLA-A*0201 in stimulating lymphocyte proliferation, but the former has no significant difference (P0.05). Therefore, HLA-A*2402 is the object of our study.
(3) a DNA vaccine containing HLA-A*2402 was constructed. Double enzyme digestion and sequencing showed that the recombinant DNA vaccine was successfully constructed.
(4) a new vaccine was constructed with HBc and HLA-A*2402 coupling (couple) with VLP as the carrier. The results of double enzyme digestion and sequencing proved that the construction was successful. The protein expression of the coupling was expressed by the baculovirus expression system. The expression of the target protein was proved by WB and electron microscopy.
(5) the immunization of Balb/c mice was carried out with the new vaccine of VLP as the carrier, and the constructed DNA vaccine was used as the control. The results showed that the new vaccine immunized with VLP as the carrier produced effective specific humoral immunity and cell immunity. The specific IgG1/IgG2a of the antibody subtype was less than 1, indicating that the Th1 type was produced. The immune response.T lymphocyte proliferation test proved that the proliferation response of spleen T lymphocyte in immunized mice was enhanced by ConA, and ELISPOT analysis showed that the number of CD8+T cells that secreted IFN- gamma in the vaccine immunization group was significantly more than that of the control group; FCM detection showed that the CD4+/CD8+ ratio of the immunization group was significantly lower than that of the control group. These results suggest that a new type of vaccine with VLP as the carrier induces specific CD8+T lymphocyte response. Both the stimulated cell immunity and the humoral immunity are obviously superior to that of the DNA vaccine control group.
(6) the study confirms that HLA-A*2402 plays an important role in the immunotherapy of children with nephroblastoma, and a new vaccine with VLP as the carrier provides a new way of thinking for the immunotherapy of tumor.
Conclusion: the new vaccine with VLP as the carrier can stimulate both humoral and cellular immunity in mice. It is superior to the corresponding DNA vaccine and provides new methods and ideas for the immunotherapy of tumor. The results need to be further validated by animal models of tumor.
【學(xué)位授予單位】：內(nèi)蒙古農(nóng)業(yè)大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2007
【分類號(hào)】：R392

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張濱;王政;;腎母細(xì)胞瘤免疫治療中的細(xì)胞毒T淋巴細(xì)胞效應(yīng)[J];南方醫(yī)科大學(xué)學(xué)報(bào);2009年07期

2 沈慧玲;WT1基因與白血病靶向治療[J];國外醫(yī)學(xué).輸血及血液學(xué)分冊(cè);2003年05期

3 樊衛(wèi)平;王宏偉;;WT1肽疫苗的研究現(xiàn)狀和發(fā)展方向[J];國際腫瘤學(xué)雜志;2006年04期

4 王政;劉貴麟;;腎母細(xì)胞瘤WT1基因研究進(jìn)展[J];臨床小兒外科雜志;2006年05期

5 王政;段躍強(qiáng);羅德炎;王希良;劉貴麟;;DNA免疫激發(fā)針對(duì)腎母細(xì)胞瘤CTL效應(yīng)初步研究[J];免疫學(xué)雜志;2007年03期

6 林東軍;李旭東;黃仁魏;劉加軍;方志剛;;WT1致敏樹突狀細(xì)胞激活CTLs對(duì)HL60細(xì)胞作用的研究[J];中華腫瘤防治雜志;2006年19期

7 閆萌;王巍;楊小昂;張毓;尹艷慧;陳慰峰;;FATE/BJ-HCC-2基因表達(dá)促進(jìn)細(xì)胞增殖及腫瘤形成[J];中國生物化學(xué)與分子生物學(xué)報(bào);2008年08期

8 郭立麗;劉少揚(yáng);江大瓊;;WT1在上皮性卵巢癌中的表達(dá)及意義[J];現(xiàn)代腫瘤醫(yī)學(xué);2007年03期

9 孔艷青;孫振柱;;WT1與NF-кB在卵巢漿液性腫瘤中的表達(dá)及意義[J];新疆醫(yī)科大學(xué)學(xué)報(bào);2011年04期

10 林東軍;方志剛;李旭東;劉加軍;陸英;;抗原沖擊致敏樹突狀細(xì)胞誘導(dǎo)特異性CTL殺傷Jurkat細(xì)胞實(shí)驗(yàn)研究[J];中國實(shí)驗(yàn)血液學(xué)雜志;2006年04期

相關(guān)博士學(xué)位論文 前10條

1 田衛(wèi)偉;WT1抗原多表位基因疫苗設(shè)計(jì)及免疫原性研究[D];山西醫(yī)科大學(xué);2011年

2 王景福;WT1在神經(jīng)母細(xì)胞瘤發(fā)生和分化中的作用[D];天津醫(yī)科大學(xué);2011年

3 湯旭東;肝素酶不同CTL表位混合多肽疫苗抗腫瘤效應(yīng)的實(shí)驗(yàn)研究[D];第三軍醫(yī)大學(xué);2011年

4 郭愛林;肝癌抗原肽的分離、純化、鑒定及抗原肽疫苗的研究[D];第四軍醫(yī)大學(xué);2001年

5 任育紅;新型重組別藻藍(lán)蛋白亞基的表達(dá)和生物活性的初步研究[D];中國科學(xué)院研究生院（海洋研究所）;2005年

6 顧偉英;WT1基因及其異構(gòu)體在白血病中表達(dá)與臨床應(yīng)用[D];蘇州大學(xué);2005年

7 樊衛(wèi)平;WT1肽疫苗體外及小鼠體內(nèi)抗瘤效應(yīng)的研究[D];山西醫(yī)科大學(xué);2006年

8 朱雄鵬;重組腺病毒介導(dǎo)Survivin和GM-CSF基因修飾樹突狀細(xì)胞體外誘導(dǎo)抗血液腫瘤免疫的實(shí)驗(yàn)研究[D];福建醫(yī)科大學(xué);2006年

9 王政;小兒腎母細(xì)胞瘤免疫治療的初步研究[D];中國人民解放軍軍醫(yī)進(jìn)修學(xué)院;2007年

10 霍曉溪;WT1在卵巢癌中的表達(dá)及其反義核酸誘導(dǎo)卵巢癌細(xì)胞凋亡的實(shí)驗(yàn)研究[D];第二軍醫(yī)大學(xué);2008年

相關(guān)碩士學(xué)位論文 前9條

1 苑曉娟;WT1-DNA疫苗聯(lián)合小劑量環(huán)磷酰胺抗腫瘤效應(yīng)的研究[D];山西醫(yī)科大學(xué);2011年

2 劉強(qiáng);PTD介導(dǎo)BCR/ABL蛋白細(xì)胞轉(zhuǎn)導(dǎo)及免疫原性的研究[D];中國人民解放軍第四軍醫(yī)大學(xué);2003年

3 徐凱紅;Prame基因在白血病和多發(fā)性骨髓瘤中的表達(dá)及臨床意義[D];重慶醫(yī)科大學(xué);2003年

4 魏琛;RNA干擾對(duì)白血病細(xì)胞WT1基因表達(dá)及細(xì)胞增殖的影響[D];鄭州大學(xué);2006年

5 谷敏;RNA干擾對(duì)WT1基因表達(dá)的抑制作用[D];蘇州大學(xué);2006年

6 楊杰斌;WT-1、P53、MMP-9和TIMP-2在卵巢漿液性乳頭狀癌中的表達(dá)及意義[D];重慶醫(yī)科大學(xué);2008年

7 張盈盈;卵巢顆粒細(xì)胞瘤中WT-1蛋白、AMH和Ki-67的表達(dá)及其意義的研究[D];山西醫(yī)科大學(xué);2009年

8 成楓;WT1基因及蛋白在急性髓細(xì)胞白血病患者中的表達(dá)和臨床意義[D];青島大學(xué);2010年

9 譚萍;小兒腎母細(xì)胞瘤中PRL-3的表達(dá)及其臨床意義[D];重慶醫(yī)科大學(xué);2012年

，

本文編號(hào)：2147928